Dr. Mark Huberman MD

Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer

Kartik Sehgal, Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C. McDonald, Cynthia R. Cherry, Meghan Shea, Mark S. Huberman, Paul A. VanderLaan, Glen J. Weiss, Paul R. Walker, Daniel B. Costa, Deepa Rangachari

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer.

Joel W. Neal, Daniel B. Costa, Alona Muzikansky, Joseph B. Shrager, Michael Lanuti, James Huang, Kavitha J Ramachandran, Deepa Rangachari, Mark S. Huberman, Zofia Piotrowska, Mark G. Kris, Christopher G. Azzoli, Lecia V. Sequist, Jamie E. Chaft

Erratum: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas (Clinical Cancer Research (2018) 24 (6548–6555) DOI: 10.1158/1078-0432.CCR-18-1541)

Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu Kobayashi, Daniel B. Costa

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Susan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R Oxnard, Deepa Rangachari, Mark S Huberman, Lecia V Sequist, Susumu S Kobayashi, Daniel B Costa

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.

Zofia Piotrowska, Daniel B. Costa, Geoffrey R. Oxnard, Mark S. Huberman, Justin F. Gainor, Inga T. Lennes, Alona Muzikansky, Alice T. Shaw, Christopher G. Azzoli, Rebecca S. Heist, Lecia V. Sequist

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer

Lorena Ostios-Garcia, Jennifer Faig, Giulia Costanza Leonardi, Anika E. Adeni, S. Subegdjo, Christine A. Lydon, Deepa Rangachari, Mark S. Huberman, Kartik Sehgal, Meghan Shea, Paul A. VanderLaan, Matthew P. Cheng, Francisco M. Marty, Sarah P. Hammond, Daniel B. Costa, Mark M. Awad

Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

Paul A. VanderLaan, Deepa Rangachari, Adnan Majid, Mihir Parikh, Sidharta P. Gangadharan, Michael S. Kent, Danielle C. McDonald, Mark S. Huberman, Susumu Kobayashi, Daniel B. Costa

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

Deepa Rangachari, Xiuning Le, Meghan Shea, Mark S. Huberman, Paul A. VanderLaan, Susumu Kobayashi, Daniel B. Costa

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma

Deepa Rangachari, Paul A. VanderLaan, Meghan Shea, Xiuning Le, Mark S. Huberman, Susumu Kobayashi, Daniel B. Costa

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

Paul A. VanderLaan, Deepa Rangachari, Susan M. Mockus, Vanessa Spotlow, Honey V. Reddi, Joan Malcolm, Mark S. Huberman, Loren Joseph, Susumu Kobayashi, Daniel B. Costa

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

Yuri Sheikine, Deepa Rangachari, Danielle C. McDonald, Mark S. Huberman, Erik S. Folch, Paul A. VanderLaan, Daniel B. Costa

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

Antonio R. Lucena-Araujo, Jason P. Moran, Paul A. VanderLaan, Dora Dias-Santagata, Erik Folch, Adnan Majid, Michael S. Kent, Sidharta P. Gangadharan, Deepa Rangachari, Mark S. Huberman, Susumu Kobayashi, Daniel B. Costa

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma

Meghan Shea, Mark S. Huberman, Daniel B. Costa

Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma.

Helen M. Shields, Justin W. Li, Stephen R. Pelletier, Helen H. Wang, Rachel A. Freedman, Harvey J. Mamon, Andrea K. Ng, Arnold S. Freedman, Steven E. Come, David Avigan, Mark S. Huberman, Abram Recht

Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas

Daniel B. Costa, Susan E. Jorge, Jason P. Moran, Jason A. Freed, Jessica A. Zerillo, Mark S. Huberman, Susumu Kobayashi

Rapidly fatal advanced EGFR -mutated lung cancers and the need for rapid tumor genotyping in clinical practice

Deepa Rangachari, Lauren Drake, Mark S. Huberman, Danielle C. McDonald, Paul A. VanderLaan, Erik Folch, Daniel B. Costa

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Susan E. Jorge, Sol Schulman, Jason A. Freed, Paul A. VanderLaan, Deepa Rangachari, Susumu Kobayashi, Mark S. Huberman, Daniel B. Costa

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

Xiuning Le, Jason A. Freed, Paul A. VanderLaan, Mark S. Huberman, Deepa Rangachari, Susan E. Jorge, Antonio R. Lucena-Araujo, Susumu Kobayashi, Sohail Balasubramanian, Jie He, Yakov Chudnovsky, Vincent A. Miller, Siraj M. Ali, Daniel B. Costa

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers

Deepa Rangachari, Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, Anand Mahadevan, Scott R. Floyd, Erik J. Uhlmann, Eric S. Wong, Suzanne E. Dahlberg, Mark S. Huberman, Daniel B. Costa

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors

Xiuning Le, Neelam V. DeSai, Adnan Majid, Rebecca Karp, Mark S. Huberman, Deepa Rangachari, Michael S. Kent, Sidhu P. Gangadharan, Erik Folch, Paul A. VanderLaan, Daniel B. Costa

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice

Deepa Rangachari, Paul A. VanderLaan, Xiuning Le, Erik Folch, Michael S. Kent, Sidhu P. Gangadharan, Adnan Majid, Richard L. Haspel, Loren Joseph, Mark S. Huberman, Daniel B. Costa

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer

Paul A. VanderLaan, Norihiro Yamaguchi, Erik Folch, David Boucher, Michael S. Kent, Sidhu P. Gangadharan, Adnan Majid, Michael A. Goldstein, Mark S. Huberman, Olivier Kocher, Daniel B. Costa

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer.

Hiroyuki Yasuda, Eun Young Park, Cai Hong Yun, Natasha J. Sng, Antonio R. Lucena-Araujo, Wee-Lee Yeo, Mark S. Huberman, David W. Cohen, Sohei Nakayama, Kota Ishioka, Norihiro Yamaguchi, Megan Hanna, Geoffrey R. Oxnard, Christopher S. Lathan, Teresa Moran, Lecia V. Sequist, Jamie E. Chaft, Gregory J. Riely, Maria E. Arcila, Ross A. Soo, Matthew Meyerson, Michael J. Eck, Susumu Kobayashi, Daniel B. Costa

Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.

Erik Folch, Norihiro Yamaguchi, Paul A. VanderLaan, Olivier Kocher, David Boucher, Michael A. Goldstein, Mark S. Huberman, Michael S. Kent, Sidharta P. Gangadharan, Daniel B. Costa, Adnan Majid

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice

Norihiro Yamaguchi, Paul A. VanderLaan, Erik Folch, David Boucher, Hannah M. Canepa, Michael S. Kent, Sidhu P. Gangadharan, Adnan Majid, Olivier Kocher, Michael A. Goldstein, Mark S. Huberman, Daniel B. Costa

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

Mark A. Socinski, Jonathan H. Goldman, Iman El-Hariry, Marianna Koczywas, V. Vukovic, Leora Horn, Eugene Paschold, Ravi Salgia, Howard West, Lecia V. Sequist, Philip Bonomi, Julie R. Brahmer, Lin-Chi Chen, Alan Sandler, Chandra P. Belani, Timothy Webb, Harry D. Harper, Mark S. Huberman, Suresh S. Ramalingam, Kwok-Kin Wong, Florentina Teofilovici, Wei Guo, Geoffrey I. Shapiro

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

Susumu Kobayashi, Hannah M. Canepa, Alexandra S. Bailey, Sohei Nakayama, Norihiro Yamaguchi, Michael A. Goldstein, Mark S. Huberman, Daniel B. Costa

Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center.

Kim-Son H. Nguyen, Rachel A. Sanford, Mark S. Huberman, Michael A. Goldstein, Danielle M. McDonald, Mary Farquhar, Sidharta P. Gangadharan, Michael S. Kent, Gaetane Michaud, Adnan Majid, Stuart M. Berman, Joseph A. Aronovitz, Elena Nedea, Phillip M. Boiselle, David W. Cohen, Susumu Kobayashi, Daniel B. Costa

Patterns of care for non-small cell lung cancer at an academic institution affiliated with a National Cancer Institute-designated cancer center: Beth Israel Deaconess Medical Center.

Nguyen KH, Huberman M, Goldstein M, Kobayashi S, Costa DB

Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer

Gregory J. Britt, Elizabeth M. Gaughan, Kim Nguyen, Jeremy L. Warner, Michael A. Goldstein, Mark S. Huberman, Daniel B. Costa

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Joel W. Neal, Rebecca S. Heist, Panos Fidias, Jennifer S. Temel, Mark S. Huberman, J. Paul Marcoux, Alona Muzikansky, Thomas J. Lynch, Lecia V. Sequist

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

Wee-Lee Yeo, Gregory J. Riely, Beow Y. Yeap, Michelle W. Lau, Jeremy L. Warner, Kelly A. Bodio, Mark S. Huberman, Mark G. Kris, Daniel G. Tenen, William Pao, Susumu Kobayashi, Daniel B. Costa

Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer

Lecia V. Sequist, Panos Fidias, Jennifer S. Temel, Tatjana Kolevska, Michael S. Rabin, Ralph V. Boccia, Howard A. Burris, R. J. Belt, Mark S. Huberman, Ostap Melnyk, Glenn Mills, Craig W. Englund, David C. Caldwell, James G. Keck, Lisa Meng, Marsha Jones, Gail L. Brown, Martin J. Edelman, Thomas J. Lynch

Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience.

Chao Ye, Justin R. Masterman, Mark S. Huberman, Sidhu P. Gangadharan, Danielle C. McDonald, Malcolm M. DeCamp

Bevacizumab reverses cerebral radiation necrosis.

Eric T. Wong, Mark S. Huberman, X. Q. Lu, Anand Mahadevan

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Daniel B. Costa, Kim Nguyen, Byoung Chul Cho, Lecia V. Sequist, David M. Jackman, Gregory J. Riely, Beow Y. Yeap, Balazs Halmos, Joo Hang Kim, Pasi A. Jänne, Mark S. Huberman, William Pao, Daniel G. Tenen, Susumu Kobayashi

A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.

Rebecca S. Heist, Panos Fidias, Mark S. Huberman, Blair Ardman, Lecia V. Sequist, Jennifer S. Temel, Thomas J. Lynch

Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib.

Costa DB, Cho BC, Sequist LV, Riely GJ, Halmos B, Kim J, Huberman MS, Pao W, Tenen DG, Kobayashi S

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

Daniel B. Costa, Balazs Halmos, Amit Kumar, Susan Schumer, Mark S. Huberman, Titus J. Boggon, Daniel G. Tenen, Susumu Kobayashi

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

Daniel B. Costa, Susumu Kobayashi, Daniel G. Tenen, Mark S. Huberman

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial

Tomislav Dragovich, Mark S. Huberman, Daniel D. Von Hoff, Eric K. Rowinsky, Paul I. Nadler, Debra L. Wood, Marta Hamilton, George Hage, Julie Wolf, Amita Patnaik

Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer.

Prudence Lam, Stuart M. Berman, Robert L. Thurer, Simon Ashiku, Malcolm M. DeCamp, Michael Goldstein, Susan Schumer, Balazs Halmos, Daniel D. Karp, Danielle Coute, Mark Bergman, Cynthia Boyd-Sirard, Sai Hong Ou, Alona Muzikansky, Cally Woodard, Mark S. Huberman

Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib

Daniel B. Costa, Mark S. Huberman

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

David M. Jackman, Beow Y. Yeap, Lecia V. Sequist, Neal I. Lindeman, Alison J. Holmes, Victoria A. Joshi, Daphne W. Bell, Mark S. Huberman, Balazs Halmos, Michael S. Rabin, Daniel A. Haber, Thomas J. Lynch, Matthew Meyerson, Bruce E. Johnson, Pasi A. Jänne

Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC).

Sequist LV, Fidias P, Temel J, Kennedy BA, Ostler PA, Rabin MS, Huberman M, Keck J, Brown GL, Lynch TJ

Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer.

Stephen A. Mayer, Aaron M. Cypess, Olivier Kocher, Stuart M. Berman, Mark S. Huberman, Pamela Hartzband, Balazs Halmos

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Roman Perez-Soler, Abraham Chachoua, Lisa A. Hammond, Eric K. Rowinsky, Mark S. Huberman, Daniel D. Karp, James Rigas, Gary M. Clark, Pedro Santabarbara, Philip Bonomi

Is Residual Confounding a Reasonable Explanation for the Apparent Protective Effects of Beta-carotene Found in Epidemiologic Studies of Lung Cancer in Smokers?

Daniel O. Stram, Mark S. Huberman, Anna H. Wu

Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer.

Zbigniew Petrovich, Gary Lieskovsky, John P. Stein, Mark S. Huberman, Donald G. Skinner

Nonrandomized comparison of surgery with and without adjuvant pelvic irradiation for patients with pT3N0 adenocarcinoma of the prostate.

Zbigniew Petrovich, Gary Lieskovsky, Bryan Langholz, Mark S. Huberman, Oscar E. Streeter, Donald G. Skinner

Gemcitabine pulmonary toxicity: CT features.

Phillip M. Boiselle, Martina M. Morrin, Mark S. Huberman

Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa

J. M. Rabey, I Sagi, Mark S. Huberman, Eldad Melamed, Amos D. Korczyn, Nir Giladi, Rivka Inzelberg, Ruth Djaldetti, Colin Klein, G Berecz

Application of the missing-indicator method in matched case-control studies with incomplete data

Mark S. Huberman, Bryan Langholz

Ascertainment bias in rate ratio estimation from case-sibling control studies of variable age-at-onset diseases.

Bryan Langholz, Argyrios Ziogas, Duncan C. Thomas, Cheryl L. Faucett, Mark S. Huberman, Larry Goldstein

Correcting for exposure measurement error in a reanalysis of lung cancer mortality for the Colorado Plateau Uranium Miners cohort.

Daniel O. Stram, Bryan Langholz, Mark S. Huberman, Duncan Thomas

Re: "Combined analysis of matched and unmatched case-control studies: comparison of risk estimates from different studies".

Mark S. Huberman, Bryan Langholz

Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: A phase II trial

Pedro M. Sanz-Altamira, Liam D. Spence, Mark S. Huberman, Marshall R. Posner, Glenn Steele, Laura J. Perry, Keith Stuart

Trials of 9‐Amino‐20(S)‐Camptothecin in Boston

Joseph Paul Eder, Eric J. Rubin, Richard Stone, Margaret Bryant, Guanxian Xu, Jeffrey G. Supko, Nancy M. Kinchla, Thomas J. Lynch, Selwyn J. Hurwitz, Dee Rodriguez, Charles L. Shapiro, Deborah Toppmeyer, Michael L. Grossbard, Evan Vosburg, Mark S. Huberman, Lowell E. Schnipper, Lawrence N. Shulman, Donald Kufe

5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.

Keith Stuart, Judy Tessitore, Mark S. Huberman

Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma

Keith Stuart, Marshall R. Posner, Kathleen Campbell, Mark S. Huberman

Influence of multimodality therapy on the management of pancreas carcinoma

J. Milburn Jessup, Marshall R. Posner, Mark S. Huberman

Impact of combined modality therapy on the treatment of adenocarcinoma of the colon

Marshall R. Posner, Ronald Bleday, Mark S. Huberman, J. M. Jessup, Paul M. Busse, Glenn Steele

Efficacy of multimodality therapy in gastric adenocarcinoma.

J. M. Jessup, Mitchell C. Posner, Mark S. Huberman, J. Loclcero, Michael D. Stone, G. Stele

Non-Hodgkin's lymphoma of the kidney with inferior vena caval extension.

Robert C. Eyre, Mark S. Huberman, Karoly Balogh

Ruderman-Kittel-Kasuya-Yosida interaction in thin wires.

Gerd Bergmann, William Shieh, Mark S. Huberman

A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors.

Mark S. Huberman, Harriet A. Bering, B. Fallon, J. Tessitore, H. Sonnenborn, Paul S, J. Zeffren, D. Levitt, Jerome E. Groopman

A pilot study of sphincter-sparing management of adenocarcinoma of the rectum.

Glenn Steele, Paul M. Busse, Mark S. Huberman, Jean M. LeClair, Z. Myron Falchuk, Robert J. Mayer, Albert Bothe, Thanjavur S. Ravikumar, Michael D. Stone, J. Milburn Jessup

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.

Abraham Mittelman, Mark S. Huberman, C. Puccio, B. Fallon, J. Tessitore, S. Savona, Robert C. Eyre, Gafney E, M. Wick, A. Skelos, P. Arnold, Tauseef Ahmed, Jerome E. Groopman, Zalmen A. Arlin, J. Zeffren, D. Levitt

Interferon alfa-induced cardiac dysfunction.

Mylan C. Cohen, Mark S. Huberman, Richard W. Nesto

Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial.

Murray M. Bern, Jacob J. Lokich, Sabina R. Wallach, Albert Bothe, Peter N. Benotti, Charles F. Arkin, Frank A. Greco, Mark S. Huberman, Cheryl Moore

Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age.

Murray M. Bern, Sabina R. Wallach, Charles F. Arkin, Jacob J. Lokich, Mark S. Huberman, N R Anderson, J C Corkery, Paul S, D F Phillips, H A Sonneborn

Vinblastine plus cisplatin in advanced non-small cell lung cancer: lack of advantage for vinblastine infusion schedule.

Mark S. Huberman, Jacob J. Lokich, Greene R, Paul S, D F Phillips, Henry Sonneborn, Zipoli T

Non-human primate (baboon) anti-carcinoembryonic antigen antibody infusion in patients with metastatic adenocarcinoma. A phase I study.

Mark S. Huberman, Jacob J. Lokich, Thomas Hill, A. Kaldany, Amin I. Kassis, T Price, C Moore, Sarah Davis, P Kasulis, Anthony P. Monaco

Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer.

Harry W. Matelski, Greene R, Mark S. Huberman, Jacob J. Lokich, Zipoli T

Apparent Transmission of Human T-Cell Leukemia Virus Type III to a Heterosexual Woman with the Acquired Immunodeficiency Syndrome

Jerome E. Groopman, M. G. Sarngadharan, Syed Zaki Salahuddin, Richard Buxbaum, Mark S. Huberman, Joan Kinniburgh, Ann Sliski, Mary F. McLane, Myron Essex, Robert C. Gallo

Adriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small cell lung cancer.

Harry W. Matelski, Jacob J. Lokich, Mark S. Huberman, Zipoli T, Paul S, Henry Sonneborn, Donald Philips

Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma.

Mark S. Huberman

Phase II trial of cisplatin in small cell carcinoma of the lung.

R. M. Levenson, Daniel C. Ihde, Mark S. Huberman, M. H. Cohen, P. A. Bunn, John D. Minna

Prospective Staging Evaluation of Patients with Cutaneous T-Cell Lymphomas: Demonstration of a High Frequency of Extracutaneous Dissemination

Paul A. Bunn, Mark S. Huberman, Jacqueline Whang-Peng, Geraldine P. Schechter, J. G. Guccion, Mary J. Matthews, Adi F. Gazdar, N. R. Dunnick, A. B. Fischmann, Daniel C. Ihde, Martin H. Cohen, B. Fossieck, John D. Minna

Hepatic involvement in the cutaneous T-cell lymphomas: results of percutaneous biopsy and peritoneoscopy.

Mark S. Huberman, Paul A. Bunn, Mary J. Matthews, Daniel C. Ihde, Adi F. Gazdar, Martin H. Cohen, John D. Minna

Herpes zoster and small cell bronchogenic carcinoma

Mark S. Huberman, Byron E. Fossieck, Paul A. Bunn, Martin H. Cohen, Daniel C. Ihde, John D. Minna